Clovis Oncology Announces First Patient Treated with Hydrobromide Salt Tablet Formulation of CO-1686 in its Ongoing Phase I/II Clinical Study

August 28, 2013

CO-1686 is a novel, oral, targeted irreversible inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) to treat non-small cell lung cancer (NSCLC) with initial activating mutations as well as the dominant resistance mutation T790M.
More »

Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment - Resistant Cancers

August 27, 2013

Syndax is advancing epigenetic therapies for treatment resistant cancers, including a Phase 3 study of entinostat in metastatic breast cancer. Participating investors included, Domain Associates, MPM Capital, Forward Ventures, RusnanoMedInvest (RMI).
More »

Applied Proteomics Inc. Completes $28 Million Series C Financing

August 20, 2013

The Series C funding will be used to commercialize a blood test for colorectal cancer, which kills 50,000 each year in the U.S. The company will be able to capitalize on the significant unmet need of directing high-risk patients toward colonoscopy.
More »